Heart Surgery for Women: Sex-Specific Considerations.
Women undergoing cardiac surgery face a distinct set of challenges rooted in biological differences that affect surgical technique, outcomes, and recovery. Despite cardiovascular disease being the leading cause of death for women in the United States, women are underrepresented in cardiac surgery clinical trials (typically comprising only 25-30% of study participants), meaning that much of the evidence guiding surgical practice was generated predominantly from male patients. The key biological differences affecting cardiac surgery in women include: smaller coronary arteries (average LAD diameter 2.4 mm in women vs 2.9 mm in men), smaller body surface area requiring different prosthesis sizing, higher rates of microvascular coronary disease (which is not amenable to bypass surgery), hormonal effects on coagulation and inflammation, and differences in left ventricular remodeling in response to valve disease. These differences have clinical consequences — women have historically had higher operative mortality for CABG than men, though contemporary data suggests this gap is narrowing as awareness of sex-specific surgical needs grows. Recognizing and accounting for these differences is essential to providing equitable cardiac surgical care for women.
What the evidence shows.
The STS National Database consistently shows that women have higher operative mortality for isolated CABG than men (2.5% vs 1.5%), even after risk adjustment. However, this gap varies significantly by center — high-volume centers with awareness of sex-specific technical considerations report smaller or no gender disparities. Women have smaller coronary arteries on average, leading to higher rates of graft failure with saphenous vein grafts and stronger relative benefit from internal mammary artery (IMA) grafts. For valve surgery, the gender mortality gap is smaller: women have comparable outcomes to men for aortic valve replacement, and may have slightly better outcomes for mitral valve repair. A 2022 Circulation meta-analysis of over 500,000 patients found that women are less likely to be offered minimally invasive approaches, less likely to receive bilateral IMA grafts, and less likely to be referred for valve repair — suggesting referral bias rather than biological unsuitability.
Current recommendations.
Current recommendations for optimizing cardiac surgery outcomes in women include: (1) use of internal mammary artery grafts in all women undergoing CABG (Class I recommendation, same as men), with consideration of bilateral IMA grafts when appropriate; (2) sex-appropriate prosthesis sizing for valve replacement, with attention to patient-prosthesis mismatch (which disproportionately affects women due to smaller annular size); (3) consideration of minimally invasive approaches, which may benefit women through reduced wound complications (women have lower sternal wound infection rates overall but higher rates of seroma and superficial wound issues); (4) recognition that chest pain presentations in women are more often atypical, and cardiac catheterization findings may show non-obstructive disease or microvascular dysfunction requiring medical management rather than surgery; (5) hormone replacement therapy management: discontinuation of estrogen-containing HRT 4-6 weeks preoperatively to reduce thrombotic risk.
Why this matters for your decision.
Women are more likely to have their cardiac symptoms dismissed, less likely to be referred for surgery, and less likely to receive the same surgical options as men. A second opinion ensures that sex-specific considerations are accounted for in the surgical plan — including appropriate grafting strategy, prosthesis sizing, and whether the coronary disease pattern is truly amenable to surgical revascularization or would be better managed medically.
Need help with this decision?
Our Heart Team evaluates your specific situation with AI-augmented analysis and dual-physician review.